Select All | None | words selected.

Top 50 Keywords:
injection
inn
infusion
immunology
immunoglobulin
monoclonal
nomenclature
peptide
drug
disease
protein
biotechnology
biotech
biosimilar
biological
antibody
mab
receptor
cancer
leukemia
immune
interleukin
asthma
tumor
factor
oncology
inhibitor
antibody-drug
atcll
afucosylated
psoriasis
autoimmune
epidermal
growth
cell
metastatic
blockade
acute
ozogamicin
calicheamicin
ccr4
sezary
chronic
mycosis
mogamulizumab
lymphoma
eosinophilic
fungoides
toxicity
checkpoint

Other Keywords:
ctcl
chemokine
cd194
cytotoxic
conjugate
lichen
kidney
organ
immunosuppressant
il-2
allergen
hypophosphatemia
chimeric
subtilisin
evolocumab
high
hyperlipidemia
kexin
ldl
pcsk9
plasma
proprotein
breakthrough
cd25
burosumab
rejection
krn23
orphan
osteomalacia
phex
rickets
x-linked
basiliximab
planus
ctla-4
transplant
molecule
cavity
cd3
epcam
epithelial
fluid

hybrid
malignant
metastasis
peritoneal
ascites
rat-mouse
eosinophil
il-5
inflammation
mepolizumab
severe
benralizumab
cd125
catumaxomab
adhesion
transplantation
immuno-oncology
cd33
fatal
gemtuzumab
myeloid
antigen
combination
cholesterol
ctla4
immunotherapy
panitumumab
ipilumab
lymphocyte
lymphocyte-associated
melanoma
neoantigen
biomarker
egfr
her1
kras
convertase
squamous
blood
her2
willebrand
breast

cd340
erbb-2
erbb2
generic
her2/neu
vhh
human
kinase
neu
overexpression
proto-oncogene
resistance
trastuzumab
von
thrombotic
ccr5
spontaneous
allergy
e
fc
hypersensitivity
ige
omalizumab
sensitivity
urticaria
thrombosis
aggregation
bivalent
caplacizumab
platelet
purpura
single-domain
thrombocytopenic
tyrosine
cd4
tildrakizumab
inotuzumab
allergic
cd11a
efalizumab
recombinant
withdrawn

cd22
liver
programmed
lymphoblastic
cytokine
il-23
il-23p19
inflammatory
interleukin-23
system
skin
pd-1
cxcr4
cluster
entry
hiv
ibalizumab
post-attachment
calca
calcb
calcitonin-related
fremanezumab
myeloma
headache
ligand
migraine
cd279
cemiplimab
death
lung
interleukin-5